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Background: The adoption of new medicines is influenced by a complex set of social processes that have been
widely examined in terms of individual prescribers’ information-seeking and decision-making behaviour. However,
quantitative, population-wide analyses of how long it takes for new healthcare practices to become part of
mainstream practice are rare.
Methods: We applied a Bass diffusion model to monthly prescription volumes of 103 often-prescribed drugs in
Australia (monthly time series data totalling 803 million prescriptions between 1992 and 2010), to determine the
distribution of adoption rates. Our aim was to test the utility of applying the Bass diffusion model to national-scale
prescribing volumes.
Results: The Bass diffusion model was fitted to the adoption of a broad cross-section of drugs using national
monthly prescription volumes from Australia (median R2 = 0.97, interquartile range 0.95 to 0.99). The median time to
adoption was 8.2 years (IQR 4.9 to 12.1). The model distinguished two classes of prescribing patterns – those where
adoption appeared to be driven mostly by external forces (19 drugs) and those driven mostly by social contagion
(84 drugs). Those driven more prominently by internal forces were found to have shorter adoption times (p = 0.02
in a non-parametric analysis of variance by ranks).
Conclusion: The Bass diffusion model may be used to retrospectively represent the patterns of adoption exhibited
in prescription volumes in Australia, and distinguishes between adoption driven primarily by external forces such as
regulation, or internal forces such as social contagion. The eight-year delay between the introduction of a new
medicine and the adoption of the prescribing practice suggests the presence of system inertia in Australian
prescribing practices.
Keywords: Adoption, Diffusion of innovation, Decision-making, Prescribing behaviour, Australia, Evidence-based
practiceBackground
Problematic uptake of evidence into clinical practice is
seen as a fundamental problem in delivering quality and
safety in healthcare – both because the adoption of new
evidence is seen as being too slow [1-3], and because fac-
tors other than evidence appear to have a strong influence
over clinical decision-making, particularly for prescription
medicines. Since the seminal work on the adoption of new* Correspondence: a.dunn@unsw.edu.au
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reproduction in any medium, provided the ormedicines was published in the 1960s [4-7], relatively little
attention has been paid to measuring population-wide
adoption of prescription drugs in healthcare. The inter-
vening period has seen dramatic increases in the volume
of published evidence [8,9], the rise of me-too drugs [10],
and increasing concerns about the confluence of clinical
evidence and marketing [11-15]. Given these changes, a
renewed interest in measuring adoption and understand-
ing the factors that contribute to the adoption of new
medicines into clinical practice is warranted.
For individual clinicians outside of acute care settings,
decision-making is known to be driven by exposure totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[16], clinical practice guidelines and other forms of
synthesised evidence, subsidisation, and the advice of
colleagues and perceived local consensus [17-23]. Using
individual choices to replicate or predict adoption at
population-wide levels has been attempted using agent-
based models [24,25].
At population-wide scales, investigations into patterns
of adoption have measured adoption times using a var-
iety of models [26,27]. Cohen [28] looked for differences
in adoption patterns for pioneers (first-in-class drugs)
versus followers (me-too drugs), without finding a gen-
eral explanation. Yet others have examined the effects of
changing evidence on practices that are already embed-
ded in mainstream practice [29,30], and the reasons for
differences in prescribing practices between countries
[31]. Diffusion of innovation theory includes a set of
models that aim to represent or predict the adoption
patterns of new technology, products or ideas [32].
Mathematical models representing diffusion of
innovation have been extensively reviewed [33-35].
These models are used to predict market penetration
and adoption rate by analogously comparing them
across products and environments, as well as forecasting
market penetration and adoption rate using early time
series data – with varied success.
The Bass diffusion model [36-40] is the most common
mathematical representation of diffusive adoption, de-
scribing the number of new adopters per unit time by
the additive effects of external (designated by a param-
eter p in the model) and internal (designated by a par-
ameter q in the model) forces (Figure 1), which may be
useful when examining the factors contributing to an
adoption rate. The Bass diffusion model has been
demonstrated as a reliable model for hundreds of new
innovations, often repeated in multiple marketplaces
(such as different countries), and the consistency of theFigure 1 The characteristic adoption curve as described by the Bass d
adoption curve (inset) comprise the internal and external factors. In this art
reaches 95 % of the population in approximately 12 years.model has been examined in several meta-analyses and
reviews [35,40,41].
The aims of the present study were to evaluate the
Bass diffusion model in its ability to represent the pre-
scription patterns of medicines introduced in Australia.
A secondary aim was to provide descriptive statistics for
adoption times of subsidised medicines in Australia.
Methods
Study data
Monthly prescription volumes for 103 drugs were
retrieved from January 1992 to December, 2009 from
aggregated, routinely collected data from the Drug Util-
isation Database maintained by the Drug Utilisation
Subcommittee (DUSC) of the Australian Pharmaceutical
Benefits Advisory Committee (PBAC). Ethics approval
was not required. Where a medicine was prescribed in
more than one form, the data were aggregated into a
single time series. Only those drugs with first recorded
prescriptions after January 1992 were included in the
analysis. The drugs were chosen to be representative of
the set of drugs that are commonly-prescribed in Aus-
tralia, other than over-the-counter drugs. The set is dis-
tributed across 11 of the 14 anatomical main groups, 33
different therapeutic subgroups including 65 pharmaco-
logical subgroups in the Anatomical Therapeutic Chem-
ical classification. Note that in cases where a drug was
represented in more than one group, we assigned it to a
single group associated with the most common reason
for prescription.
Importantly, some of the drugs included in the set
have been shown to be unsafe or not cost-effective in re-
lation to existing drugs following new published evi-
dence within the time frame of the study, which may
have a delayed or reduced effect on prescribing prac-
tices. The most prominent are rosiglitazone and rofe-
coxib, which were later withdrawn or restricted aroundiffusion model. The contributions to the S-shaped cumulative
ificial example created using typical values for p and q, the adoption
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drugs provided cost reductions or slight gains in efficacy
or safety rather than new molecular entities designed to
fill an unmet need in the therapeutic class [46,47]. These
characteristics are not considered in the analysis.
Study Design
Raw monthly prescription volumes exhibit seasonal and
safety net fluctuations [27], so they are smoothed (using
a moving average over non-zero values) and then nor-
malised by the population growth in Australia to give
the number of prescriptions per 100,000 Australians.
The smoothed and normalised monthly prescription
volumes were used to represent the cumulative percent-
age of adoption by fitting them to the Bass diffusion
model (Figure 2). The model was fitted using a non-
linear least squares analysis from MatlabW 7.11.1 (The
MathWorks, Natick, MA). The resulting values for p
and q were used to classify the adoptions as either
external-dominant (p > q) or internal-dominant (p < q),
following van den Bulte & Stremersch [40].
The adoption time of a practice is defined to be the
number of months between the first recorded prescription
and the modelled estimate of 95% of the maximum
monthly prescription rate (chosen arbitrarily to represent
near-saturation as the model asymptotes at the max-
imum). In searching for factors associated with fast or
slow adoption, correlations between the adoption time
and specific factors that might be expected to influence
adoption were considered. Firstly, the medicines were
categorised by anatomical groups (via the Anatomical
Therapeutic Chemical classification) and differences in
adoption times were considered across the larger groups.
Secondly, the adoptions were placed in two groups repre-
senting the strength of internal and external forces – those
in which external forces were dominant, and those for
which internal forces were dominant. In both cases, the
statistical comparisons were performed using a Kruskal-Figure 2 The pattern of adoption for sertraline in Australia. The patter
volumes indicating the seasonal and safety net fluctuations (blue), and the
adoption period (to 90 % of saturation) was between mid-1994 and the mWallis test – a non-parametric analysis of variance across
two or more groups. All tests were performed using
MatlabW 7.11.1 (The MathWorks, Natick, MA).
A single class of drugs was used to illustrate order of
market entry and system inertia. The drug class chosen
was HMG CoA reductase inhibitors (statins). High choles-
terol is the third largest contributor of risk to mortality
worldwide behind smoking and high blood pressure [48].
Statins are the most common pharmacological treatments
for the condition, and are recommended as best practice
following lifestyle changes [49]. The cross-section of drugs
included four statins, totalling 17.3 million prescriptions
in Australia in 2009, and these were illustrated alongside
simvastatin, which was introduced prior to 1992.
Results
Patterns of adoption
The Bass diffusion model was fitted to the prescription
volumes of 103 medicines that were introduced between
1992 and 2009 (Table 1). After fitting the model using a
non-linear least squares analysis, the median adjusted R2
value for the 103 adoptions is 0.97 with an inter-quartile
range of 0.95 to 0.99, indicating an accurate fit. These
values are similar to those reported for other products out-
side of healthcare delivery [50]. The results indicate that the
median estimated adoption time is 8.2 years, with a rela-
tively wide inter-quartile range of 4.9 years to 12.1 years.
To determine if the type of condition or therapeutic
group had an influence over the rate of adoption, we
tested for differences in the adoption times between
Therapeutic subgroups (according to the Anatomical
Therapeutic Chemical classification). Across the 10
therapeutic subgroups that included four or more drugs
from our set (for a total of 67 medicines), no significant
differences were found in the adoption times using an
analysis of variance by ranks (p = 0.19).
The drugs were grouped according to those in which
external forces were predominant (for 19 drugs, valuesn of adoption for sertraline is given by the raw monthly prescription
Bass diffusion model estimate of the adoption over time (black). The
iddle of 2003.









p/q ratio from Bass
diffusion model




Alimentary tract and metabolism
Esomeprazole Mar 2002 2755 5.87×10-1 0.990 8.67
Clarithromycin* Dec 1998 384 1.50×109 0.865 14.08
Granisetron Dec 2003 45 3.30×10-2 0.986 5.58
Ursodeoxycholic acid* Jun 2000 13 8.50×109 0.948 9.75
Balsalazide Mar 2005 9 1.08×10-1 0.995 4.58
Insulin lispro Jun 1996 30 4.52×10-1 0.973 6.75
Insulin glargine May 2006 113 5.57×10-1 0.961 5.50
Glimepiride Jun 2000 263 3.40×10-2 0.981 2.42
Rosiglitazone Jun 2003 228 3.40×10-2 0.969 4.17
Pioglitazone Jun 2003 226 1.21×10-1 0.912 8.83
Acarbose Jun 1997 38 6.20×10-2 0.991 2.25
Blood and blood forming organs
Enoxaparin Nov 1993 123 4.00×10-3 0.990 14.42
Clopidogrel Apr 1999 1327 2.69×10-1 0.994 11.33
Ticlopidine Nov 1992 15 1.90×10-2 0.976 6.08
Dipyridamole Mar 1999 74 1.10×10-2 0.962 1.17
Abciximab Dec 1995 2 5.00×10-2 0.965 5.83
Tirofiban Jun 1999 1 3.37×10-1 0.979 4.92
Cardiovascular system
Nicorandil Sep 1997 110 6.97×10-1 0.979 13.58
Eplerenone Sep 2005 5 1.19×10-1 0.986 5.00
Bisoprolol Mar 2002 211 2.80×10-2 0.983 9.08
Carvedilol Dec 1997 256 1.39×10-1 0.991 9.50
Amlodipine* Mar 1993 1378 1.86×109 0.863 12.92
Lisinopril Apr 1992 744 1.79×10-1 0.992 4.92
Perindopril Mar 1992 3174 4.60×10-2 0.991 18.08
Ramipril Apr 1992 1550 5.60×10-2 0.976 14.83
Quinapril Sep 1992 453 8.00×10-3 0.953 7.25
Fosinopril* Apr 1992 491 2.45 0.933 8.75
Trandolapril Nov 1994 424 6.90×10-2 0.980 4.58
Eprosartan Apr 1999 98 3.50×10-2 0.983 6.25
Irbesartan Dec 1997 3333 6.51×10-1 0.992 9.33
Candesartan Sep 1998 1640 1.02×10-1 0.995 11.83
Telmisartan Jun 1999 1535 1.07×10-1 0.969 12.25
Pravastatin Jan 1993 895 9.20×10-2 0.991 10.58
Fluvastatin Sep 1995 223 2.80×10-2 0.952 1.83
Atorvastatin Sep 1997 5096 8.67×10-1 0.987 13.42
Rosuvastatin Jun 2006 1967 3.60×10-2 0.990 3.83
Fenofibrate Mar 2004 250 3.00×10-2 0.991 6.00
Ezetimibe* Mar 2004 419 1.30 0.974 6.17
Dermatologicals
Fluconazole* May 1992 11 2.83×108 0.909 23.33
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Imiquimod Nov 2005 14 1.33×10-1 0.952 1.42
Fluticasone Mar 1995 552 1.20×10-2 0.979 5.17
Tacrolimus Mar 2003 6 2.46×10-1 0.967 9.92
Finasteride* Jun 1995 25 1.71 0.838 18.50
Genito urinary system and sex hormones
Raloxifene May 1999 153 4.80×10-2 0.994 2.75
Alprostadil Jun 1995 64 2.00×10-3 0.989 2.42
Antiinfectives for systemic use
Roxithromycin Jun 1992 1244 7.50×10-1 0.972 5.33
Azithromycin Jan 1995 47 1.26×10-1 0.916 17.17
Itraconazole* Jun 1997 3 1.94×108 0.955 8.75
Famciclovir* Jun 1995 64 4.79×1011 0.902 17.08
Valaciclovir Mar 1996 160 1.54×10-1 0.997 13.50
Antineoplastic and immunomodulating agents
Temozolomide Sep 1999 5 5.98×10-1 0.910 12.33
Gemcitabine Dec 1995 9 2.08×10-1 0.974 8.50
Capecitabine* Jun 1999 9 2.22 0.928 8.58
Vinorelbine Jun 1998 1 4.10×10-2 0.980 2.00
Paclitaxel May 1994 9 2.96×10-1 0.942 17.92
Docetaxel Mar 1996 9 5.39×10-1 0.850 19.25
Oxaliplatin Jun 2001 8 4.46×10-1 0.971 5.00
Rituximab Sep 1998 18 1.85×10-1 0.983 10.50
Imatinib Jul 2001 9 1.70×10-2 0.976 1.92
Irinotecan Dec 1999 5 8.00×10-3 0.865 1.08
Nilutamide Dec 1996 2 3.10×10-2 0.977 1.92
Anastrozole Mar 1997 89 2.00×10-3 0.982 12.42
Letrozole Dec 1997 51 6.00×10-2 0.928 15.42
Exemestane Aug 2000 9 2.03×10-1 0.921 11.67
Interferon beta1a* Sep 1998 16 2.87×107 0.977 9.75
Interferon alfa2a Jul 1992 1 1.20×10-2 0.900 8.33
Leflunomide* Sep 1999 78 2.87×109 0.948 12.58
Etanercept Mar 2003 27 8.60×10-2 0.989 7.58
Adalimumab Dec 2003 36 1.90×10-2 0.980 6.92
Musculo-skeletal system
Rofecoxib Jun 2000 1281 1.40×10-2 0.963 1.75
Celecoxib Jun 1999 1806 2.00×10-3 0.981 1.58
Alendronic acid Jun 1996 955 9.00×10-3 0.991 8.25
Risedronic acid Sep 2000 583 6.20×10-2 0.993 8.42
Nervous system
Fentanyl Mar 1999 203 6.00×10-3 0.910 12.25
Tramadol Apr 1999 954 1.10×10-2 0.962 4.33
Oxcarbazepine* May 1999 6 3.84 0.955 8.42
Lamotrigine Jul 1994 146 7.11×10-1 0.984 17.17
Topiramate Mar 1997 87 1.80×10-1 0.921 18.25
Gabapentin Jul 1994 75 8.10×10-2 0.974 14.67
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Flupentixol Mar 1994 8 4.99×10-1 0.988 5.08
Zuclopenthixol Jun 1996 10 1.21×10-1 0.956 6.83
Olanzapine* Mar 1997 391 1.87 0.961 11.08
Quetiapine Jun 2000 262 5.90×10-2 0.950 11.75
Amisulpride Mar 2002 36 8.60×10-2 0.952 2.42
Risperidone Sep 1994 268 9.10×10-2 0.927 17.67
Aripiprazole* Dec 2003 47 5.50 0.975 5.50
Citalopram Sep 1997 757 6.30×10-2 0.994 5.50
Paroxetine Mar 1994 581 1.33×10-1 0.996 5.92
Sertraline Mar 1994 1181 3.55×10-1 0.985 9.67
Fluvoxamine Mar 1997 183 2.21×10-1 0.997 8.00
Venlafaxine Mar 1996 1167 1.15×10-1 0.990 12.83
Methylphenidate Feb 2005 156 6.50×10-2 0.992 3.92
Donepezil Apr 1999 102 3.83×10-1 0.955 6.75
Rivastigmine Mar 2000 13 1.00×10-3 0.946 1.42
Galantamine Jun 2001 47 1.10×10-1 0.996 4.92
Acamprosate Jun 1999 12 2.40×10-2 0.944 0.92
Riluzole* Feb 2003 3 3.49×105 0.975 6.08
Respiratory system
Nedocromil Nov 1994 115 5.00×10-2 0.986 2.08
Salmeterol Sep 1994 1362 1.10×10-2 0.944 10.00
Formoterol Dec 1996 644 8.90×10-2 0.948 16.75
Tiotropium* Sep 2002 748 3.537 0.969 8.50
Montelukast* Sep 2002 78 4.82 0.969 7.08
Sensory organs
Latanoprost* Dec 1997 689 2.99×109 0.923 7.92
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terisk in Table 1) and those in which the forces were
evenly distributed or predominantly driven by internal
forces (84 drugs). Under an analysis of variance by rank,
the larger group of drugs, in which internal forces
appeared to be dominant, was found to have significantly
shorter adoption times (p = 0.02).
Statins as an example of drug class adoptions
In Australia, HMG CoA reductase inhibitors (statins)
were prescribed around 1.4 million times every month.
There has been a rapid expansion of the market for
cholesterol-lowering drugs, more than ten times the rate
of prescription in 1992, which may be attributed to
increased prevalence, increased diagnosis and increased
marketing. New statins do not appear to subsume mar-
ket share although simvastatin, fluvastatin and pravasta-
tin have decreased in volume since the introduction of
rosuvastatin. In 2009, the two predominant and increas-
ing statins in the market were atorvastatin and rosuvas-
tatin, which were first prescribed under subsidy inSeptember 1997 and June 2006, respectively. The indi-
vidual growth in prescriptions for all four of the statins
introduced since 1996 conform to the pattern of diffu-
sive adoption that appears to be common across the ma-
jority of drugs prescribed in Australia (Figure 3). The
rate of adoption across the group does not match the
order of entry or the maximum monthly prescription
volumes. The lack of an obvious pattern is consistent
with other drug classes in the study, and with a previous
study on order of entry [46].
Discussion
The results indicate that although the Bass diffusion
model is capable of modelling adoption of new medi-
cines in Australia, the adoption times of commonly-
prescribed medicines are highly variable. The medicines
in which internal forces were dominant in the adoption
exhibited significantly faster adoption relative to their
externally-dominant counterparts. However, the result
should be interpreted with some caution. The internal/
external divide does not appear to correspond to order
Figure 3 The prescribing patterns of statins in Australia. Cumulative prescription volumes for the four statins in the study (pravastatin,
fluvastatin, atorvastatin and rosuvastatin), and prescription volumes for simvastatin, which was first prescribed under subsidy prior to 1992.
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subgroup of the medicines in the sample. So while the
Bass diffusion model suggests that two classes of adop-
tion are present in the healthcare system (a result that
also corresponds to current opinion, other markets and
is exhibited at scale of the individual clinician), the result
does not help to prospectively predict faster adoption of
new medicines.
The limitations of the present study include the rela-
tively small number of drugs in the anatomical groups,
implying that an insignificant difference between groups
may be a consequence of the sample size rather than an
indication that the conditions or drug groups have little
effect on overall adoption rates. Other limitations in-
clude the potential for bias associated with drugs that
have not reached saturation – those predictions are
likely to be less accurate regardless of how well the
model fits for the available data. Other limitations spe-
cific to the mathematical modelling of adoption, both
using the Bass diffusion model and more generally, are
reported elsewhere [40,51-53].
The results show that internal forces such as social
contagion are important factors affecting the adoption of
new medicines. This finding is reflected in discussions
around the perceptions of evidence [1], and studies dem-
onstrating the presence of social contagion in the prolif-
eration of evidence and opinion [54].
The effects of external forces such as the characteris-
tics of medicines, competition, marketing effort and the
dynamic production of evidence are considered as a sin-
gle force in the Bass diffusion model. The median result
for the time to saturation (8.2 years) suggests the pres-
ence of system inertia [55]. Fuchs and Milstein [2] pro-
vided a series of financial and social reasons for why
clinicians and the organisations that support their
decision-making are resistant to adopting cost-effectivepractices. It would be worthwhile modelling the different
external factors explicitly in future studies.Conclusions
Alongside other models of adoption, the Bass diffusion
model is capable of representing general adoption pat-
terns for a broad range of medicines introduced and
subsidised in Australia. The model estimates the con-
tributions of internal and external factors that drive
adoption and separate adoption patterns into two dis-
tinct categories. The wide range of adoption times
revealed, and the lack of simple predictors to explain
this variance, suggest that factors other than condi-
tion/class and order of entry affect a healthcare sys-
tem’s response to the introduction of new medicines.
Factors that are not considered in the model that may
contribute to the variability include competition be-
tween interventions in the same class, the relative
strength of marketing, and the effects of a highly dy-
namic evidence-base supporting the comparative effect-
iveness of medicines in each class.
The presence of system inertia suggests that the flow
of new evidence into practice, and the rate of change
of prescribing practices are important factors in deter-
mining how closely clinical decision-making reflects
current perceptions of comparative effectiveness and
safety. As a consequence, further research in the area
would benefit from considering explicit links between
the micro-scale of individual clinical decision-making
and perceptions of evidence, the meso-scale of social
contagion and marketing, and the macro-scale of regu-
lation and competition.Competing interests
The authors declare that they have no competing interests.
Dunn et al. BMC Health Services Research 2012, 12:248 Page 8 of 9
http://www.biomedcentral.com/1472-6963/12/248Authors’ contributions
AD conceived of the study, performed the analysis, and drafted the
manuscript. BG and EC participated in the conception, analysis and
coordination of the study, and contributed to critical revisions of the
manuscript. JB, WR and RD participated in the conception of the study and
contributed to the critical revisions of the manuscript. All authors read and
approved the final manuscript.Acknowledgements
The research was funded by NHMRC Program Grant 568612. The funding
body had no role in the research. Prescription volumes were provided by
the DUSC Drug Utilisation Database, © Commonwealth of Australia.
Author details
1Centre for Health Informatics, Australian Institute of Health Innovation,
University of New South Wales, Sydney 2052, NSW, Australia. 2Centre for
Clinical Governance Research in Health, Australian Institute of Health
Innovation, University of New South Wales, Sydney, Australia. 3Department of
Clinical Pharmacology, St Vincent’s Hospital, University of New South Wales,
Sydney, Australia. 4School of Psychology, Social Work and Social Policy,
University of South, Sydney, Australia.
Received: 10 January 2012 Accepted: 2 August 2012
Published: 10 August 2012References
1. Berwick DM: Disseminating Innovations in Health Care. JAMA 2003,
289(15):1969–1975.
2. Fuchs VR, Milstein A: The $640 Billion Question - Why Does Cost-Effective
Care Diffuse So Slowly? N Engl J Med 2011, 364(21):1985–1987.
3. Kotchen TA: Why the Slow Diffusion of Treatment Guidelines Into Clinical
Practice? Arch Intern Med 2007, 167(22):2394–2395.
4. Coleman J, Katz E, Menzel H: The Diffusion of an Innovation Among
Physicians. Sociometry 1957, 20(4):253–270.
5. Coleman J, Katz E, Menzel H: Medical Innovation: A Diffusion Study.
Indianapolis: The Bobbs-Merrill Company; 1966.
6. Menzel H: Innovation, Integration, and Marginality: A Survey of
Physicians. Am Sociol Rev 1960, 25(5):704–713.
7. Winick C: The Diffusion of an Innovation Among Physicians in a Large
City. Sociometry 1961, 24(4):384–396.
8. Bastian H, Glasziou P, Chalmers I: Seventy-Five Trials and Eleven
Systematic Reviews a Day: How Will We Ever Keep Up? PLoS Med
2010, 7(9):e1000326.
9. Fraser AG, Dunstan FD: On the impossibility of being expert. BMJ
2010, 341.
10. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR,
Schacht AL: How to improve R&D productivity: the pharmaceutical
industry's grand challenge. Nat Rev Drug Discov 2010, 9:203–214.
11. Brody H, Light DW: The Inverse Benefit Law: How Drug Marketing
Undermines Patient Safety and Public Health. Am J Public Health 2011,
101(3):399–404.
12. DeAngelis CD, Fontanarosa PB: Impugning the Integrity of Medical Science:
The Adverse Effects of Industry Influence. JAMA 2008, 299(15):1833–1835.
13. Lathyris DN, Patsopoulos NA, Salanti G, Ioannidis JPA: Industry sponsorship
and selection of comparators in randomized clinical trials. Eur J Clin Invest
2010, 40(2):172–182.
14. Lenzer J: Many US medical associations and disease awareness
groups depend heavily on funding by drug manufacturers. BMJ 2011,
342:d2929.
15. Lundh A, Barbateskovic M, Hróbjartsson A, Gøtzsche PC: Conflicts of
Interest at Medical Journals: The Influence of Industry-Supported
Randomised Trials on Journal Impact Factors and Revenue - Cohort
Study. PLoS Med 2010, 7(10):e1000354.
16. Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, Othman N,
Vitry AI: Information from Pharmaceutical Companies and the Quality,
Quantity, and Cost of Physicians' Prescribing: A Systematic Review. PLoS
Med 2010, 7(10):e1000352.
17. Doumit G, Gattellari M, Grimshaw J, O'Brien MA: Local opinion leaders:
effects on professional practice and healthcare outcomes. Cochrane
Database Syst Rev 2007, 1:CD000125.18. Mintzes B: For and against: Direct to consumer advertising is
medicalising normal human experience. BMJ 2002, 324(7342):908–909.
19. Mintzes B, Barer ML, Kravitz RL, Kazanjian AE, Bassett K, Lexchin J, Evans RG,
Pan R, Marion SA: Influence of direct to consumer pharmaceutical
advertising and patients' requests on prescribing decisions: two site
cross sectional survey. BMJ 2002, 324(7332):278–279.
20. Prosser H, Almond S, Walley T: Influences on GPs' decision to prescribe new
drugs–the importance of who says what. Fam Pract 2003, 20(1):61–68.
21. Prosser H, Walley T: New drug prescribing by hospital doctors: The nature
and meaning of knowledge. Soc Sci Med 2006, 62(7):1565–1578.
22. Peay MY, Peay ER: Differences among practitioners in patterns of
preference for information sources in the adoption of new drugs. Soc Sci
Med 1984, 18(12):1019–1025.
23. Peay MY, Peay ER: Patterns of preference for information sources in the
adoption of new drugs by specialists. Soc Sci Med 1990, 31(4):467–476.
24. Ratna N, Dray A, Perez P, Grafton R, Newth D, Kompas T: Diffusion and
Social Networks: Revisiting Medical Innovation with Agents. Complex
Decision Making 2008, 30:247–265.
25. Dunn AG, Gallego B, Diffusion of competing innovations: The effects of
network structure on the provision of healthcare. The Journal of Artificial
Societies and Social Simulation 2010, 13:4.
26. Balas EA, Boren SA: Managing clinical knowledge for health care
improvement. In: Yearbook of Medical Informatics 2000. In Patient-
Centered Systems. 65th edition. Edited by Bemmel J, McCray AT. Stuttgart,
Germany: Schattauer Verlagsgesellschaft mbH; 2000.
27. Birkett DJ, McManus P: Modelling the market uptake of new drugs
following listing for subsidy in Australia. A report from the Drug
Utilisation Subcommittee of the Australian Pharmaceutical Benefits
Advisory Committee. Br J Clin Pharmacol 1995, 40(4):407–410.
28. Brennan TA, Rothman DJ, Blank L, Blumenthal D, Chimonas SC, Cohen JJ,
Goldman J, Kassirer JP, Kimball H, Naughton J, et al: Health Industry
Practices That Create Conflicts of Interest: A Policy Proposal for
Academic Medical Centers. JAMA 2006, 295(4):429–433.
29. Lamas GA, Pfeffer MA, Hamm P, Wertheimer J, Rouleau J-L, Braunwald E: Do
the Results of Randomized Clinical Trials of Cardiovascular Drugs
Influence Medical Practice? N Engl J Med 1992, 327(4):241–247.
30. Stafford RS, Furberg CD, Finkelstein SN, Cockburn IM, Alehegn T, Ma J:
Impact of Clinical Trial Results on National Trends in β-Blocker
Prescribing, 1996-2002. JAMA 2004, 291(1):54–62.
31. Jackevicius CA, Tu JV, Ross JS, Ko DT, Carreon D, Krumholz HM: Use of
Fibrates in the United States and Canada. JAMA 2011, 305(12):1217–1224.
32. Rogers EM: Diffusion of Innovations. 5th edition. New York: Free Press; 2003.
33. Mahajan V, Muller E: Innovation Diffusion and New Product Growth
Models in Marketing. J Mark 1979, 43(4):55–68.
34. Mahajan V, Muller E, Bass FM: New Product Diffusion Models in Marketing:
A Review and Directions for Research. J Mark 1990, 54(1):1–26.
35. Meade N, Islam T: Modelling and forecasting the diffusion of innovation -
A 25-year review. Int J Forecast 2006, 22(3):519–545.
36. Bass FM: A New Product Growth for Model Consumer Durables. Manag
Sci 1969, 15(5):215–227.
37. Bass FM: Comments on "A New Product Growth for Model Consumer
Durables": The Bass Model. Manag Sci 2004, 50(12):1833–1840.
38. Bemmaor AC, Lee J: The Impact of Heterogeneity and Ill-Conditioning on
Diffusion Model Parameter Estimates. Mark Sci 2002, 21(2):209–220.
39. Norton JA, Bass FM: A Diffusion Theory Model of Adoption and
Substitution for Successive Generations of High-Technology Products.
Manag Sci 1987, 33(9):1069–1086.
40. van den Bulte C, Stremersch S: Social Contagion and Income
Heterogeneity in New Product Diffusion: A Meta-Analytic Test. Mark Sci
2004, 23(4):530–544.
41. Talukdar D, Sudhir K, Ainslie A: Investigating New Product Diffusion across
Products and Countries. Mark Sci 2002, 21(1):97–114.
42. Cohen D: Rosiglitazone: what went wrong? BMJ 2010, 341:c4848.
43. Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M: Risk of
cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet
2004, 364(9450):2021–2029.
44. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial
infarction and death from cardiovascular causes. N Engl J Med 2007,
356(24):2457–2471.
45. Topol EJ: Failing the Public Health - Rofecoxib, Merck, and the FDA. N
Engl J Med 2004, 351(17):1707–1709.
Dunn et al. BMC Health Services Research 2012, 12:248 Page 9 of 9
http://www.biomedcentral.com/1472-6963/12/24846. Cohen FJ: Entry order as a consideration for innovation strategies. Nat
Rev Drug Discov 2006, 5(4):285–294.
47. DiMasi JA, Paquette C: The Economics of Follow-on Drug Research and
Development: Trends in Entry Rates and the Timing of Development.
PharmacoEconomics 2004, 22:1–14.
48. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL: Global and
regional burden of disease and risk factors, 2001: systematic analysis of
population health data. Lancet 2006, 367(9524):1747–1757.
49. Expert Panel on Detection E: Treatment of High Blood Cholesterol in A:
Executive Summary of the Third Report of the National Cholesterol
Education Program (NCEP) Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel
III). JAMA 2001, 285(19):2486–2497.
50. Wright M, Upritchard C, Lewis T: A Validation of the Bass New Product
Diffusion Model in New Zealand. Mark Bull 1997, 8:15–29.
51. Fruchter GE, Van den Bulte C: Why the Generalized Bass Model leads to
odd optimal advertising policies. Int J Res Mark, 28(3):218–230.
52. Jiang Z, Bass FM, Bass PI: Virtual Bass Model and the left-hand data-
truncation bias in diffusion of innovation studies. Int J Res Mark 2006,
23(1):93–106.
53. van den Bulte C, Lilien GL: Bias and Systematic Change in the Parameter
Estimates of Macro-Level Diffusion Models. Mark Sci 1997, 16(4):338–353.
54. Iyengar R, Van den Bulte C, Valente TW: Opinion Leadership and Social
Contagion in New Product Diffusion. Mark Sci 2011, 30(2):195–212.
55. Coiera E: Why system inertia makes health reform so difficult. BMJ 2011,
342:d3693.
doi:10.1186/1472-6963-12-248
Cite this article as: Dunn et al.: Nation-scale adoption of new medicines
by doctors: an application of the Bass diffusion model. BMC Health
Services Research 2012 12:248.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
